Duchenne muscular dystrophy (DMD) is a rare genetic disease affecting 1 in 5000 newborn boys. It is caused by mutations in the DMD gene with a consequent lack of dystrophin protein that leads to deterioration of myofibers and their replacement with fibro-adipogenic tissue. Using antisense oligonucleotides (AONs) to modify out-of-frame mutations in the DMD gene, named exon skipping, is currently considered among the most promising treatments for DMD patients. The development of this strategy is rapidly moving forward, and AONs designed to skip exons 51 and 53 have received accelerated approval in the USA. In preclinical setting, the mdx mouse model, carrying a point mutation in exon 23 of the murine Dmd gene that prevents production of dystrophin protein, has emerged as a valuable tool, and it is widely used to study in vivo therapeutic approaches for DMD. Here we describe the methodology for intravenous delivery of AONs targeting dystrophin through tail vein of mdx mice. Furthermore, the most relevant functional analyses to be performed in living mice, and the most informative histopathological and molecular assays to evaluate the effect of this treatment are detailed.
|Title of host publication||Antisense RNA Design, Delivery and Analysis|
|Editors||Virginia Arechavala-Gomeza, Alejandro Garanto|
|Number of pages||13|
|Publication status||Published - 25 Feb 2022|
|Name||Methods in Molecular Biology|
Bibliographical noteFunding Information:
The authors thank the Muscular Dystrophy UK (London, UK) for funding the study (grant reference number: RA/893) and Sarepta Therapeutics Inc. (Cambridge, Massachusetts, USA) for their sponsorship. The authors declare that they have no conflict of interest.
© 2022, The Author(s).